New possibilities for the treatment of neovascular AMD. The real clinical practice
https://doi.org/10.25789/YMJ.2022.79.07
Abstract
The results of treatment of patients with neovascular age-related macular degeneration with a modern anti-angiogenic drug registered in Russia in November 2020 were analyzed. After three intravitreal injections in the recommended Treat&Extend regimen, the patients showed positive dynamics in both anatomical and functional parameters during the examination.
About the Authors
E. K. Zakharova
Yakut Republican Ophthalmologic Clinic RS(Ya);
Medical Institute, M.K. Ammosov Yakutsk State Medical University
Russian Federation
Russian Federation
Zakharova Ekaterina Kimovna – Candidate of Medical Sciences, Head of the Department of the Yakut Republican Ophthalmologic Clinic RS(Ya), Associate Professor of the Basic Department of Ophthalmology of the Medical Institute, M.K. Ammosov Yakutsk State Medical University
I. P. Lutskan
Yakut Republican Ophthalmologic Clinic RS(Ya);
Medical Institute, M.K. Ammosov Yakutsk State Medical University
Russian Federation
Russian Federation
Lutskan Ivan Petrovich – Candidate of Medical Sciences, Chief Physician of the Yakut Republican Ophthalmologic Clinic RS(Ya), Associate Professor of the Department of Public Health and Public Health, General Hygiene and Bioethics of the Medical Institute, M.K. Ammosov Yakutsk State Pedagogical University
T. R. Poskachina
Medical Institute, M.K. Ammosov Yakutsk State Medical University
Russian Federation
Russian Federation
Poskachina Tamara Romanovna – Candidate of Medical Sciences, Associate Professor, Head of the Basic Department of Ophthalmolog
References
1. Astakhov YuS. Modes of administration of angiogenesis inhibitors in the treatment of patients with neovascular age-related macular degeneration/ Astakhov YuS, Nechiporenko PA. //Ophthalmological vedomosti. - 2019. - V. 12, No. 2. - P. 47-56.
2. Bobykin EV. Treatment of macular diseases: a look into the future (literature review) / Bobykin EV. // Reflection. – 2020. - V.10, No.1. – P. 61-72.
3. Bobykin EV. Modes of application of antiangiogenic therapy for the treatment of macular diseases in ophthalmology. Literature review/ Bobykin EV. //Practical medicine. -2018. – V.16, No. 5. – P. 104-111.
4. Bobykin EV. Satisfaction with the treatment of patients with neovascular age-related macular degeneration receiving antiangiogenic therapy/ Bobykin EV, Korotkih SA, Nerus IA, Morozova OV. //Pacific Medical Journal. -2019; No. 2(76). - P. 14-18.
5. Budzinskaya MV. New qualitative methods for assessing the "fluid" in the retina in age-related macular degeneration / Budzinskaya MV, Plyukhova AA.// Ophthalmology. -2021. – V. 18, N. 2. - P. 222-227. DOI:10.18008/1816-5095-2021-2-222-227
6. Budzinskaya MV. Prospects of antiangiogenic therapy in retinal diseases / Budzinskaya MV, Plyukhova AA. // Ibid.- V.18. N. 3S. – P. 638-645. DOI:10.18008/1816-5095-2021-3S-638-645
7. Gavrilova NA. Analysis of the results of clinical studies in neovascular age-related macular degeneration for 2005-2020. Literature review / Gavrilova NA, Gadzhieva NS, Tishchenko OE, Zinovieva AV // Ibid. – 2022. – V. 19, N.1. – P. 22-32. DOI:10.18008/1816-5095-2022-1-22-32
8. Durasov AB. Therapy of neovascular age-related macular degeneration: reasonable expectations of a doctor and a patient / Durasov AB. // Clinical ophthalmology. -2021. V. 21, N. 3. P. 169-174. DOI:10.32364/2311-7729-2021-21-3-169-174
9. Ioshin IE. Approaches to the appointment of antiangiogenic drugs in the treatment of patients with neovascular age-related macular degeneration/ Ioshin I.E, Anoprieva TA. // Russian Ophthalmological Journal. – 2019. - V. 12, N. 3. – P. 102-112. DOI:10.21516/2072-0076-2019-12-3-102-112
10. Koroleva IA. Pharmacotherapy of AMD: an overview of new trends / Koroleva IA, Gvetadze AA, Romanova TB. // RMJ. Clinical ophthalmology. - 2019; - V. 19, N. 2. – P. 105-109. DOI:10.32364/2311-7729-2019-19-2-105-109
11. Medvedeva LM. Some aspects of pathogenesis and treatment of age-related macular degeneration / Medvedeva LM. // Bulletin of the Vitebsk State Medical University. -2021. - V. 20, N.5. – P. 7-14. DOI:10.22263/2312-4156.2021.5.7
12. Neroev VV. Visual disability in the Russian Federation/ Neroev VV. - SPb: ‘Belye nochi’ [White Nights]. 2017. organum-visus.com , eye-portal.ru , glaucoma-eye-portal.ru
13. The first clinical experience of using aflibercept in the treatment of patients with neovascular age-related macular degeneration resistant to ranibizumab / Zhayvoronok N. S., Egorov V. V., Smolyakova G. P. [et al.]. // Modern technologies in ophthalmology. -2018. - N. 2. – P. 144-147.
14. Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to real clinical practice/ Fayzrakhmanov RR. // Russian Ophthalmological Journal. -2019. – V.12, N. 2. – P. 97-105. DOI:10.21516/2072-0076-2019-12-2-97-105
15. Profile of ophthalmological safety of antiangiogenic therapy/ Fursova AZh, Zabanova VE, Gamza YuA [et al.].// Bulletin of Ophthalmology. -2021, - V. 137, N. 2. – P. 114-122. DOI: 10.17116/oftalma2021137021114
16. Dugel P.U., Koh A., Ogura Y. [et al.] HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration//Ophthalmology.-2020. Vol.127, N.1.URL: https://www.aaojournal.org/article/S0161-6420(18)33018-5/fulltext
17. Garca-Quintanilla L., Luaces-Rodrguez A., Gil-Martnez M. [et al.] Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration // Pharmaceutics. - 2019. Vol. 11, N. 8. P. 365. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723750/
18. Schmidt-Erfurth U., Vogl W.D., Jampol L.M., Bogunović H. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration // Ophthalmology. -2020. Vol. 127, N. 9. - P. 1211-1219. URL: https://www.sciencedirect.com/science/article/pii/S0161642020302682
19. Tadayoni R., Sararols L., Weissgerber G. [et al.] Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration // Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2021. Vol. 244. N. 2. P. 93-101. URL: https://www.karger.com/Article/FullText/513048
20. Wong W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis // Lancet Glob Health. 2014;2: e106–e116.
Review
For citations:
Zakharova E.K., Lutskan I.P., Poskachina T.R. New possibilities for the treatment of neovascular AMD. The real clinical practice. Yakut Medical Journal. 2022;(3):30-33. https://doi.org/10.25789/YMJ.2022.79.07
Views:
20
Email this article 